Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-SEROSMART): findings from national representative sample
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
OBJECTIVES: We estimated the population prevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including unreported infections, through a Korea Seroprevalence Study of Monitoring of SARS-CoV-2 Antibody Retention and Transmission (K-SEROSMART) in 258 communities throughout Korea. METHODS: In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling. During face-to-face household interviews, participants self-reported their health status, COVID-19 diagnosis and vaccination history, and general characteristics. Subsequently, participants visited a community health center or medical clinic for blood sampling. Blood samples were analyzed for the presence of antibodies to spike proteins (anti-S) and antibodies to nucleocapsid proteins (anti-N) SARS-CoV-2 proteins using an electrochemiluminescence immunoassay. To estimate the population prevalence, the PROC SURVEYMEANS statistical procedure was employed, with weighting to reflect demographic data from July 2022. RESULTS: In total, 9,945 individuals from 5,041 households were surveyed across 258 communities, representing all basic local governments in Korea. The overall population-adjusted prevalence rates of anti-S and anti-N were 97.6% and 57.1%, respectively. Since the Korea Disease Control and Prevention Agency has reported a cumulative incidence of confirmed cases of 37.8% through July 31, 2022, the proportion of unreported infections among all COVID-19 infection was suggested to be 33.9%. CONCLUSIONS: The K-SEROSMART represents the first nationwide, community-based seroepidemiologic survey of COVID-19, confirming that most individuals possess antibodies to SARS-CoV-2 and that a significant number of unreported cases existed. Furthermore, this study lays the foundation for a surveillance system to continuously monitor transmission at the community level and the response to COVID-19.
Abstract
OBJECTIVES: We estimated the population prevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including unreported infections, through a Korea Seroprevalence Study of Monitoring of SARS-CoV-2 Antibody Retention and Transmission (K-SEROSMART) in 258 communities throughout Korea. METHODS: In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling. During face-to-face household interviews, participants self-reported their health status, COVID-19 diagnosis and vaccination history, and general characteristics. Subsequently, participants visited a community health center or medical clinic for blood sampling. Blood samples were analyzed for the presence of antibodies to spike proteins (anti-S) and antibodies to nucleocapsid proteins (anti-N) SARS-CoV-2 proteins using an electrochemiluminescence immunoassay. To estimate the population prevalence, the PROC SURVEYMEANS statistical procedure was employed, with weighting to reflect demographic data from July 2022. RESULTS: In total, 9,945 individuals from 5,041 households were surveyed across 258 communities, representing all basic local governments in Korea. The overall population-adjusted prevalence rates of anti-S and anti-N were 97.6% and 57.1%, respectively. Since the Korea Disease Control and Prevention Agency has reported a cumulative incidence of confirmed cases of 37.8% through July 31, 2022, the proportion of unreported infections among all COVID-19 infection was suggested to be 33.9%. CONCLUSIONS: The K-SEROSMART represents the first nationwide, community-based seroepidemiologic survey of COVID-19, confirming that most individuals possess antibodies to SARS-CoV-2 and that a significant number of unreported cases existed. Furthermore, this study lays the foundation for a surveillance system to continuously monitor transmission at the community level and the response to COVID-19.
참고문헌 (45)
- "Rolling updates on coronavirus disease (COVID-19) updated 31 July 2020"[URL]
- "COVID-19 dashboard" (2022)[URL]
- Ashcroft P, "Test-trace-isolate-quarantine(TTIQ)intervention strategies after symptomatic COVID-19 case identification", PLoS One, 17, pp.e0263597~ (2022)
- 윤규현, "Seroprevalence of SARS-CoV-2 antibodies during the third wave of COVID-19 in the Seoul metropolitan area of Korea", Epidemiology and Health, 44, pp.1~8 (2022), 한국역학회[DOI]
- Yanes-Lane M, "Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential : a systematic review and meta-analysis", PLoS One, 15, pp.e0241536~ (2020)
- Zou L, "SARS-CoV-2 viral load in upper respiratory specimens of infected patients", N Engl J Med, 382, pp.1177~1179 (2020)
- Lee S, "Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea", JAMA Intern Med, 180, pp.1447~1452 (2020)
- Gao Z, "A systematic review of asymptomatic infections with COVID-19", J Microbiol Immunol Infect, 54, pp.12~16 (2021)
- "A coordinated global research roadmap: 2019 novel coronavirus" (2020)[URL]
- "Interim guidelines for COVID-19 antibody testing" (2022)[URL]
- Bobrovitz N, "Global seroprevalence of SARS-CoV-2 antibodies : a systematic review and meta-analysis", PLoS One, 16, pp.e0252617~ (2021)
- Nah EH, "Nationwide seroprevalence of antibodies to SARS-CoV-2 in asymptomatic population in South Korea : a cross-sectional study", BMJ Open, 11, pp.e049837~ (2021)
- "Key insights" (2022)[URL]
- Bergeri I, "Global SARS-CoV-2 seroprevalence from January 2020 to April 2022 : a systematic review and meta-analysis of standardized population-based studies", PLoS Med, 19, pp.e1004107~ (2022)
- Elliott P, "Population monitoring of SARS-CoV-2 infections via random sampling during the COVID-19 pandemic", Am J Public Health, 113, pp.514~516 (2023)
- "Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors: round 3 update" (2022)[URL]
- Clarke KE, "Seroprevalence of infection-induced SARS-CoV-2 antibodies-United States, September 2021-February 2022", MMWR Morb Mortal Wkly Rep, 71, pp.606~608 (2022)
- Akinbami LJ, "SARS-CoV-2 serology and self-reported infection among adults-National Health and Nutrition Examination Survey, United States, August 2021-May 2022", MMWR Morb Mortal Wkly Rep, 71, pp.1522~1525 (2022)
- Song Suk-Kyoon, "IgG Seroprevalence of COVID-19 among Individuals without a History of the Coronavirus Disease Infection in Daegu, Korea", Journal of Korean Medical Science, 35(29), pp.1~8 (2020), 대한의학회[DOI]
- 노지윤, "Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea", Journal of Korean Medical Science, 35(33), pp.1~6 (2020), 대한의학회[DOI]
- Yang Wha Kang, "Korea Community Health Survey Data Profiles", Osong Public Health and Research Perspectives, 6(3), pp.211~217 (2015), 질병관리청
- 김영택, "지역사회건강조사의 조사 기획과 수행", 대한의사협회지, 55(1), pp.74~83 (2012), 대한의사협회
- Kweon S, "Data resource profile : the Korea National Health and Nutrition Examination Survey(KNHANES)", Int J Epidemiol, 43, pp.69~77 (2014)
- Korea community health at a glance 2020: Korea Community Health Survey (KCHS), "Korea Disease Control and Prevention Agency", Korea Disease Control and Prevention Agency, ~ (2021)
- Muench P, "Development and validation of the Elecsys Anti-SARS-CoV-2 immunoassay as a highly specific tool for determining past exposure to SARS-CoV-2", J Clin Microbiol, 58, pp.e01694~e016920 (2020)
- Gralinski LE, "Return of the coronavirus : 2019-nCoV", Viruses, 12, pp.135~ (2020)
- Lee N, "Quantitative analysis of anti-N and anti-S antibody titers of SARS-CoV-2 infection after the third dose of COVID-19 vaccination", Vaccines(Basel), 10, pp.1143~ (2022)
- Rashidzadeh H, "Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirus 2): diagnosis, treatment, therapy and future perspectives", Nanomedicine(Lond), 16, pp.497~516 (2021)
- "Guideline of sampling design and management" (2016)[URL]
- "COVID-19 for healthcare provider"[URL]
- "COVID-19 vaccination notice: 5-11 years" (2022)[URL]
- "Urging participation in COVID-19 vaccination for severe illness and mortality prevention in pediatric and adolescent populations" (2022)[URL]
- "COVID-19 vaccine surveillance report week 35" (2022)[URL]
- Inbaraj LR, "Seroprevalence of COVID-19 infection in a rural district of South India : a population-based seroepidemiological study", PLoS One, 16, pp.e0249247~ (2021)
- Mohammed I, "The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality : a systematic review", Hum Vaccin Immunother, 18, pp.2027160~ (2022)
- "Urging COVID-19 vaccination for the prevention of severe illness and mortality, including older adults and other eligible individuals" (2022)[URL]
- "The results of COVID-19 antibody prevalence surveys indicate that the natural infection rate is higher than the cumulative incidence rate during the same period" (2022)[URL]
- Shakiba M, "Prevalence of asymptomatic COVID-19 infection using a seroepidemiological survey", Epidemiol Infect, 148, pp.e300~ (2020)
- Byambasuren O, "Estimating the extent of asymptomatic COVID-19 and its potential for community transmission : systematic review and meta-analysis", J Assoc Med Microbiol Infect Dis Can, 5, pp.223~234 (2020)
- Nishiura H, "Estimation of the asymptomatic ratio of novel coronavirus infections(COVID-19)", Int J Infect Dis, 94, pp.154~155 (2020)
- Abedi V, "Racial, economic, and health inequality and COVID-19 infection in the United States", J Racial Ethn Health Disparities, 8, pp.732~742 (2021)
- Garnier R, "Socioeconomic disparities in social distancing during the COVID-19 pandemic in the United States : observational study", J Med Internet Res, 23, pp.e24591~ (2021)
- Krutikov M, "Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic(VIVALDI study) : prospective cohort study in England", Lancet Healthy Longev, 3, pp.e13~e21 (2022)
- Nakagama Y, "Detecting waning serological response with commercial immunoassays : 18-month longitudinal follow-up of anti-SARS-CoV-2 nucleocapsid antibodies", Microbiol Spectr, 10, pp.e0098622~ (2022)
- Schallier A, "Assay dependence of long-term kinetics of SARS-CoV-2 antibodies", Diagn Microbiol Infect Dis, 100, pp.115403~ (2021)